Truist Financial Trims Lantheus (NASDAQ:LNTH) Target Price to $135.00

Lantheus (NASDAQ:LNTH) had its price objective reduced by Truist Financial from $141.00 to $135.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

Several other research firms also recently weighed in on LNTH. Mizuho increased their price target on shares of Lantheus from $90.00 to $100.00 and gave the stock a buy rating in a research report on Friday, May 3rd. JMP Securities raised their target price on Lantheus from $100.00 to $130.00 and gave the stock an outperform rating in a report on Wednesday, July 10th. B. Riley boosted their price target on Lantheus from $105.00 to $146.00 and gave the company a buy rating in a report on Thursday, July 25th. StockNews.com cut Lantheus from a buy rating to a hold rating in a research report on Friday, May 3rd. Finally, SVB Leerink increased their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an outperform rating in a report on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Lantheus presently has an average rating of Moderate Buy and a consensus target price of $119.00.

Lantheus Stock Performance

LNTH stock opened at $97.59 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.55. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89. The company has a market cap of $6.78 billion, a P/E ratio of 14.90 and a beta of 0.51. The stock’s fifty day moving average price is $92.18 and its 200-day moving average price is $73.12.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. During the same period in the previous year, the business posted $1.40 earnings per share. The company’s revenue for the quarter was up 22.5% on a year-over-year basis. On average, equities analysts forecast that Lantheus will post 6.46 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total value of $41,994.15. Following the transaction, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at approximately $7,661,900.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Lantheus news, insider Daniel Niedzwiecki sold 12,873 shares of the business’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $79.86, for a total value of $1,028,037.78. Following the sale, the insider now owns 80,244 shares in the company, valued at approximately $6,408,285.84. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at approximately $7,661,900.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 44,799 shares of company stock worth $3,769,262. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Lantheus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC raised its holdings in shares of Lantheus by 595.3% during the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after acquiring an additional 1,269,900 shares in the last quarter. Norges Bank bought a new stake in Lantheus in the fourth quarter worth $29,956,000. Swedbank AB purchased a new stake in Lantheus during the first quarter valued at $26,346,000. Nomura Holdings Inc. lifted its position in Lantheus by 105.3% during the fourth quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider’s stock valued at $1,282,000 after purchasing an additional 407,507 shares during the last quarter. Finally, Westfield Capital Management Co. LP grew its stake in shares of Lantheus by 25.3% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after buying an additional 394,837 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.